Sani MURAT, M. Akif ÇAKAR, Ramazan AKDEMİR, Hüseyin GÜNDÜZ, Yüksel KAYA, Ekrem YETER, Orhan BULUT, Harun KILIÇ, M. Bülent VATAN, İbrahim KOCAYİĞİT, Mehmet DOĞAN, Mustafa Tarık AĞAÇ, Zeydin ACAR

Percutaneous closure of small to moderate ventricular septal defects: Early clinical and procedural results

Amaç: Bu çalışmada, Amplatzer Septal Okluder ile perkütan Ventriküler Septal Deefekt kapatılmasıyla ilgili klinik ve işlmle ilgili sonuçlarını sunmayı amaçladık. Yöntem ve Gereçler: 2008-2011 yılları arasında, 5 kardiyoloji merkezinde, 23 hastaya, Amplatzer Septal Okluder kullanılarak başarılı Ventriküler Septal Defekt perkütan kapama işlemi uygulandı. Hastalar işlemden bir ay sonra klinik ve ekokardiyografik olarak değerlendirldi. Floroskopi süresi, işlem süresi, pulmoner şant oranı, ekokardiyografik olarak Ventriküler Septal Defekt çapları, kullanılan cihaz tipleri ve hemodinamik veriler kaydedildi. Bulgular: Hastaların tümünde işlem başarılı oldu. Floroskopi süresi 25±20 (15-112) dakika, işlem süresi 90±51 (40–145) dakikaydı. İşlem sırasında ölüm veya acil cerrahi gereksinim gerektiren komplikasyon görülmedi. Bir hastada cihaz embolizasyonu, bir hastada 3. derece atrioventriküler blok, 3 hastada cihaz içinden rezidü şant ve 3 hastada kasık bölgesinde hemotam varlığı kaydedildi. Hastaların takibinde ölüm, endokardit veya cihazla ilgili bir olumsuz olay kaydedilmedi. Bir hastada rezidü şant devam etti. Sonuç: Perkütan yolla Amplatzer Septal Okluder kullanılarak Ventriküler Septal Defekt kapatılması çok iyi işlemsel ve klinik sonuçlarla birlikte, uygulanabilir ve güvenli bir tekniktir.

Perkütan ventriküler septal defekt kapatılması: Erken dönem klinik ve işlemsel sonuçlar

Aim: In this study, we aimed to present the procedural and early clinical results percutaneous closure of Ventricular Septal Defects with Amplatzer septal occluders Materail And Methods: Between 2008 and 2011, 23 patients were underwent successfully percutaneous Ventricular Septal Defect closure in 4 cardiology centers. Percutaneous closure was performed with Amplatzer Septal Occluders. Patients were evaluated clinically and by echocardiography one month after the procedure. fluoroscopic time, procedure duration, pulmonary/systemic shunt ration, Ventricular Septal Defect diameter on echocardiography, types of devices used and hemodynamic data were all recorded. Results: Percutaneous closures of Ventricular Septal Defects were successfully performed in all patients. Fluoroscopic time (min) was 25±20 minutes (range 15–112), procedure time (min) was 90±51 (range 40–145). There was not any death or urgent cardiac surgery required complication. There was one device embolization, one third degree atrioventricular, intra device residual shunt n 3 patients for 3 days and mild groin hematoma was occurred in three patients. There was not any significant adverse event in patients group during follow-up including death, endocarditis or device related complication. Residual shunt was remained in one patient. Conclusion: Percutaneous closure of Ventricular Septal Defects with Amplatzer septal occluders is a feasible and safe technique with excellent early procedural and clinical results.

PDF

___

1. Arora R, Trehan V, Kumar A. Transcatheter closure of congenital ventricular septal defects. Experience with various devices. J Interv Cardiol 2003; 16:83–91
2. Butera G, Carminati M, Chessa M. Transcatheter closure of perimembranous ventricular septal defects early and long-term results. J Am Coll Cardiol 2007;50(12):1189–1195
3. Butera G, Carminati M, Chessa M, et al. Percutaneous closure of ventricular septal defects in children aged b 12: early and mid term results. Eur Heart J 2006; 27(23):2889–95.
4. Butera G, Chessa M, Piazza L, et.al. Percutaneous closure of ventricular septal defects. Expert Rev Cardiovasc Ther 2006; 4(5):671–80.
5. Carminati M, Butera G, Chessa M. Transcatheter closure of congenital ventricular septal defect with Amplatzer septal occluders. Am J Cardiol 2005; 96:52L–58L
6. Chaudari M, Chessa M, Stumper O, et.al. Transcatheter coils closure of muscular ventricular septal defects. J Invasive Cardiol 2001; 14:165–8.
7. Fu YC, Bass J, Amin Z, et al. Transcatheter closure of perimembranous ventricular septal defect using the new amplatzer membranous VSD Occluder. Results of the U.S. phase I trial. J Am Coll Cardiol 2006; 47: 319–25.
8. Hijazi ZM, Hakim F, Haweleh AA, et.al. Catheter closure of perimembranous ventricular septal defects using the new Amplatzer membranous VSD occluder: initial clinical experience. Cathet Cardiovasc Interv 2002; 56: 508-515.
9. Kidd L, Discroll DJ, Gersony WH. Second natural history study of congenital heart defects: results of treatment of patients with ventricular septal defects. Circulation 1993; 87: 138–151
10. Kunii Y, Kamada M, Ohtsuki S, et. al. Plasma brain natriuretic peptide and the evaluation of volume overload in infants and children with congenital heart disease. Acta Med Okayama 2003; 57(4):191-7.
11. Masura J, Gao W, Gavora P. Percutaneous closure of perimembranous ventricular septal defects with the eccentric Amplatzer device: multicenter follow-up study. Pediatr Cardiol 2005; 26:216–219
12. Pedra AC, Pedra SRF, Esteves CA. Percutaneous closure of perimembranous ventricular septal defects with the Amplatzer device: technical and morphological considerations. Catheter Cardiovasc Interv 2004; 61:403–410
13. Pinto RJ, Dalvi BV, Sharma S. Transcatheter closure of perimembranous ventricular septal defects using the Amplatzer asymmetric ventricular septal defect occluder: preliminary experience with 18-month follow-up. Catheter Cardiovasc Interv 2006; 68:145–152
14. Sanders SP, Yeager S, Williams RG. Measurement of systemic and pulmonary blood flow and Qp/Qs ratio using Doppler and two dimensional echocardiography. Am J Cardiol 1983; 51:952–956
15. Suda K, Matsumura M, Matsumoto M. Clinical implication of plasma natriuretic peptides in children with ventricular septal defect. Pediatr Int 2003; 45:249–254
16. Thanopoulos BD, Tsaousis GS, Karanasios E. Transcatheter closure of perimembranous ventricular septal defects with the Amplatzer asymmetric ventricular septal defect occluder: preliminary experience in children. Heart 2003; 89:918–922
17. Thanopoulos BD, Tsaousis GS, Konstadopoulos GN, et.al. Transcatheter closure of muscular ventricular septal defects with the Amplatzer ventricular septal defect occluder: initial clinical application in children. JAm Coll Cardiol 1999; 33:1395–1399.